1 SUPPLEMENTARY INFORMATION to

2 SARS-CoV-2 Niches in Human Placenta Revealed by Spatial Transcriptomics

- 3 Authors: Enrico R. Barrozo,¹ Maxim D. Seferovic,¹ Eumenia C.C. Castro,² Angela M. Major,² David N. Moorshead,^{1,3,4}
- 4 Michael D. Jochum,¹ Ricardo Ferral Rojas,¹ Cynthia D. Shope,¹ Kjersti M. Aagaard^{1,*}

5 Affiliations:

- 6 ¹Baylor College of Medicine and Texas Children's Hospital, Department of Obstetrics and Gynecology, Division of Maternal-
- 7 Fetal Medicine, Houston, TX, USA
- 8 ²Baylor College of Medicine and Texas Children's Hospital, Department of Pathology and Immunology, Houston, TX, USA
- 9 ³Medical Scientist Training Program, Baylor College of Medicine, Houston, TX, USA
- 10 ⁴Immunology and Microbiology Graduate Program, Baylor College of Medicine, Houston, TX, USA

11 *Correspondence:

- 12 Kjersti M. Aagaard, MD PhD
- 13 Professor and Henry & Emma Meyer Chair
- 14 Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine
- 15 Baylor College of Medicine
- 16 1 Baylor Plaza, Houston, TX 77030
- 17 aagaardt@bcm.edu
- 18 **Figure S1.** Quality control metrics of placental spatial transcriptomes, related to Figure 2.
- **Figure S2.** Visualization of viral transcription in placentae, related to Figures 2-5.
- 20 **Figure S3.** Annotation of macrophage polarization subpopulations, related to Figure 6.
- 21 Figure S4. Spatial resolution of fetal sex differences in gene expression responses to SARS-CoV-2, related to Figure 7.
- 22 **Table S1.** Compiled differential expression tables from the spatial transcriptomics analyses, related to Figures 1-7.
- 23 Uploaded separately.
- 24 Table S2. **Study population characteristics.** Significance (**P*<0.05) was determined by unpaired two-way T-tests.
- 25 Abbreviations: VBAC= vaginal birth after previous Cesarean section, NA=not applicable, ND= data not determined or not
- 26 reported, SEM= standard error of the mean).
- 27



29 Figure S1. Quality control metrics of placental spatial transcriptomes, related to Figure 2. (A) Using standard quality 30 control metrics, 18,245 spatial transcriptomes were iteratively filtered for each individual library to remove outliers, 31 resulting in 17,927 high-quality transcriptomes being retained (98%). (B) Cell cycle phase assignments for the term 32 placenta atlas. (C) The proportion of placental niches per sample. (D) Feature plots of quality control metrics for the term 33 placenta atlas. Abbreviations: nFeature= number of unique transcripts, nCount= number of unique molecule identifiers 34 (UMIs), EVT= extravillous trophoblast, VCT= villous cytotrophoblast, SYT= syncytiotrophoblast, percent.mt= the 35 percentage of mitochondrial RNAs per transcriptome, and percent.ribo= the percentage of ribosomal RNAs per 36 transcriptome.



Figure S2. Visualization of viral transcription in placentae, related to Figures 2-5. (A-D) SpatialDimPlots of SARS-CoV-2 transcripts for each placenta positive for SARS-CoV-2 by spatial transcriptomics. Note- a scale of 0 means the viral transcript was not detected in that sample and the scales for each transcript are modified to include the ranges of all

42 datapoints by default. Abbreviations: HP= highly positive, and SP= sparsely positive.



44 Figure S3. Annotation of macrophage polarization subpopulations, related to Figure 6. (A) UMAPs of macrophage spatial 45 transcriptomes color annotated by cluster, condition, or cell-cycle phase. Sx and Ax refer to clinical maternal symptomatic 46 or asymptomatic SARS-CoV-2 infections; all subjects were confirmed as SARS-CoV-2 postiive by nasopharyngeal PCR 47 testing. (B-C) Heatmaps with top markers for myeloid lineages (B) and macrophage polarization (C). (D) Density and 48 FeaturePlots visualizing expression of FOLR2 marking fetal macrophages (Hofbauer) and HLA expression marking placenta-49 associated maternal macrophages (PAMMs). Expression of CCR2 and ITGAM expression mark PAMM1 and PAMM2, 50 respectively. (E) Cell counts of macrophage polarization subpopulations displayed as percentages relative to total 51 macrophages.

Α

4 4 FCGRT FCGR1A FCGR3B Max Previously Identified Genes with IFI6 Log₂(fold-change) Fetal Sex Differences CXCL10 OAS1 CCL2 MX1 Zero IL10 IFNA1 IFNA2 IFNG CCL CD163 **Spatial Transcriptomics** scRNA-seq В С 0081 FIDE S 5 1 Max Max Log₂(fold-change) Log₂(fold-change) XAGE3 MT-CO2 TPT1 RPL10A RPL27A CD14 RPL37A MT-CD1 RPS8 MT-CD1 CG4 CG22 CRYAE GAPDI OLFAAL PPDP DP DP DP S100A1 CRSPL0 RISPLO TP, TNNT COL1A PDP GRIP E IFITM P4HA CTHRCI S100A RPINES BNIP Zero Zero

All SARS-CoV-2 Placentae Analyzed by Spatial Transcriptomics

56

57

58

59

Figure S4. Spatial resolution of SARS-CoV-2 differential transcripts by fetal sex (male, m; female, f), related to Figure 7. (A) Heatmap with the differential expression of previously identified SARS-CoV-2 genes reported to vary by fetal sex stratification (Bordt, *et al.*, Sci Transl Med. (2021)) with the SARS-CoV-2 spatial transcriptomics data plotted by fetal sex (*n*=4 male [m] and 5 female [f]). (B) Heatmap of the top 50 genes with expression differences relative to fetal sex in SARS-CoV-2 scRNA-seq data (147,906 transcriptomes; *n*=15 female and 30 male; (Garcia-Flores *et al.* **Nat Comms**. (2022)) plotted by placental niche. (C) Heatmap of the top 50 genes with expression differences relative to fetal sex in SARS-CoV-2 spatial transcriptomics data plotted by placental niche.

60 61 62 Supplementary Table 2. Study population characteristics, related to Figures 1-7. Significance (**P*<0.05) was determined by unpaired two-way T-tests.

63 Abbreviations: VBAC= vaginal birth after previous Cesarean section, NA=not applicable, ND= data not determined or not reported, SEM= standard error of the

64 mean.

		Maternal	Maternal	Control vs.	Control vs.	Control vs.	Asymptomatic vs.
	Uninfected	SARS-CoV-2	SARS-CoV-2	SARS-CoV-2	Asymptomatic	Symptomatic	Symptomatic
Variable	Control	Asymptomatic	Symptomatic	P-value	P-value	P-value	P-value
Maternal age, mean							
years (SEM)	28 (1.58)	27.33 (3.06)	26.8 (2.53)	0.922	0.856	0.952	0.917
Gravidity, mean (SEM)	4 (0.71)	3.5 (0.65)	2.2 (0.25)	0.342	0.620	0.101	0.216
Parity, mean (SEM)	2 (0.71)	1 (0.41)	0.83 (0.52)	0.296	0.267	0.206	1.000
Gestational age, mean							
weeks (SEM)	39.6 (0.34)	39.8 (0.49)	34.2 (2.81)	0.424	0.842	0.164	0.157
Birthweight, mean							
grams (SEM)	3361 (31.3)	3498 (179.2)	3228 (327.7)	0.973	0.724	0.770	0.523
Placental weight, mean							
grams (SEM)	495 (37)	509 (17.7)	412 (70.9)	0.681	0.550	0.318	0.192
Delivery Mode (%)				0.129	*0.030	0.109	0.356
Vaginal	3 (75)	0 (0)	3 (50)				
Cesarean section	1 (25)	3 (75)	3 (50)				
VBAC	0 (0)	1 (25)	0 (0)				
Ethnicity (%)				0.774	0.537	1.000	0.537
Non-Hispanic	3 (75)	2 (50)	4 (66.6)				
Hispanic	1 (25)	2 (50)	1 (20)				
Nondisclosed	0 (0)	0 (0)	1 (20)				
Fetal Sex (%)				0.48	0.537	0.356	0.798
Male	3 (75)	2 (50)	2 (33.3)				
Female	1 (25)	2 (50)	3 (50)				
Not disclosed			1 (16.6)				
COVID-19 Severity (%)				NA	NA	NA	*0.001
NA	4 (100)						
Asymptomatic		4 (100)	0 (0)				
Maternal pneumonia		0 (0)	4 (66.6)		NA	*0.035	*0.001
Maternal respiratory							
failure		0 (0)	1 (16.6)				
Intrauterine fetal		. ,	. ,				
demise		0 (0)	2 (33.3)				

Days between onset of							
(SEM)	NA	0	7 (2.2)	NA	NA	NA	*0.026